<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02553681</url>
  </required_header>
  <id_info>
    <org_study_id>CM-002-001</org_study_id>
    <nct_id>NCT02553681</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of HPT Treated Rigid Contact Lenses Made From Roflufocon D</brief_title>
  <official_title>Clinical Evaluation of Hydra-PEG (Polyethylene Glycol) Treatment (HPT) Treated Rigid Contact Lenses Made From Roflufocon D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Contamac Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hartwig Research Center</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Contamac Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be an up to six months, subject-masked, contralateral, parallel-group, randomised,&#xD;
      daily wear study. All subjects will wear the Test lens in one eye and the Control lens in the&#xD;
      other eye. Data from the first four weeks of Test and Control lens exposure will be used for&#xD;
      the FDA 510 (k) submission.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">February 16, 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>questionnaire addressing subjective comfort and wear time</measure>
    <time_frame>subjects will be followed-up for one month</time_frame>
    <description>Subjects rated on a scale from 1 to 10, where 1 was 'poor' and 10 was 'excellent'.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>conjunctival redness - ocular biomicroscopy</measure>
    <time_frame>subjects will be followed-up for one month</time_frame>
    <description>Graded based on a grading scale which ranged from 0 to 4, where 0 is none, 1 is trace, 2 is mild, 3 is moderate and 4 is severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>corneal staining - ocular biomicroscopy</measure>
    <time_frame>subjects will be followed-up for one month</time_frame>
    <description>Graded based on a grading scale which ranged from 0 to 4, where 0 is none, 1 is trace, 2 is mild, 3 is moderate and 4 is severe.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Ametropia</condition>
  <arm_group>
    <arm_group_label>HPT treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydra-PEG Treatment (HPT) treated RGP contact lenses made from roflufocon D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>untreated</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>untreated RGP contact lenses made from roflufocon D</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>roflufocon D contact lenses</intervention_name>
    <description>HPT treated rigid contact lenses</description>
    <arm_group_label>HPT treated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RGP contact lenses made from roflufocon D</intervention_name>
    <arm_group_label>untreated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to sign the informed consent form&#xD;
&#xD;
          -  Aged ≥18 years old&#xD;
&#xD;
          -  Experienced wearer of rigid gas permeable contact lenses&#xD;
&#xD;
          -  Subject's habitual contact lenses must be made of Contamac's Optimum Extra (roflufocon&#xD;
             D) material&#xD;
&#xD;
          -  Subjects must have owned spectacles or contact lenses prior to enrolment for this&#xD;
             trial&#xD;
&#xD;
          -  Spherical power between -10.00 D and +10.00 D (at vertex distance 0 mm)&#xD;
&#xD;
          -  Corneal astigmatism ≤2.00 D&#xD;
&#xD;
        Exclusion Criteria:• Eye injury or surgery within 3 months immediately prior to enrolment&#xD;
        for this trial&#xD;
&#xD;
          -  Pre-existing ocular irritation that would preclude contact lens fitting&#xD;
&#xD;
          -  Currently enrolled in an ophthalmic clinical trial&#xD;
&#xD;
          -  Evidence of systemic or ocular abnormality, infection or disease which is likely to&#xD;
             affect successful wear of contact lenses or use of the accessory solutions, as&#xD;
             determined by the investigator&#xD;
&#xD;
          -  Any use of medications for which contact lens wear could be contradicted, as&#xD;
             determined by the investigator&#xD;
&#xD;
          -  Current extended-wear users (sleep-in overnight)&#xD;
&#xD;
          -  Current monovision lens wearers&#xD;
&#xD;
          -  Current wearers of multifocal contact lenses&#xD;
&#xD;
          -  Current wearers of toric contact lenses (front surface design)&#xD;
&#xD;
          -  Current wearers of astigmatic contact lenses (posterior surface design)&#xD;
&#xD;
          -  Has a reported &quot;Strong&quot; comfort or vision preference between each eye with their&#xD;
             habitual RGP lenses&#xD;
&#xD;
          -  Unacceptable fit of habitual lenses&#xD;
&#xD;
          -  Pregnant women and nursing mothers&#xD;
&#xD;
          -  Best-corrected visual acuity worse than 6/9 (LogMAR: +0.20; Snellen decimal: 0.63)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Hartwig, PhD, FAAO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hartwig Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Siehste</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

